Evidence Updates
Retatrutide — Phase 3 Trial Complete: ~28–30% weight loss (Lilly topline).
Orforglipron — First oral GLP-1 pill, FDA-approved (FDA).
Plasma exchange — Significantly improved biological age markers in its first real RCT (Aging Cell 2025).
Rapamycin — no edge over exercise in a head-to-head RCT (J Cachexia 2026).
Watchlist
CagriSema — FDA decision ~Oct 2026; beat semaglutide head-to-head (~18% vs ~12%).
Pelacarsen (Lp(a)HORIZON) — the first-ever Lp(a) outcomes trial reads out in 2026; it defines the whole class.
Obicetrapib — could be the first CETP inhibitor ever approved; EMA decision 2H 2026.